New publication: Advances in the diagnosis of inherited neuromuscular diseases and implications for therapy development

The neuromuscular field has seen rapid advances in recent years thanks to the increased use of next-generation sequencing and additional omics technologies like RNA sequencing and proteomics. Together with colleagues from Ottawa, Germany and the UK, we were delighted to write a new review for the Lancet Neurology in which we show how these new technologies have improved diagnostic rates, increased understanding of disease mechanisms and led to new therapeutic opportunities. We also highlight the continued need for traditional evaluations and the key role that disease experts still play in interpreting the results of the new techniques as leaders of an interdisciplinary approach involving bioinformaticians and data scientists as well as the traditional clinical and biological disciplines. The article is available at the Lancet Neurology website and is temporarily open-access through this dedicated link.

 

Thompson R, Spendiff S, Roos A, Bourque PR, Warman Chardon J, Kirschner J, Rita Horvath R, Lochmüller H. Advances in the diagnosis of inherited neuromuscular diseases and implications for therapy development. Lancet Neurol. 19(6) 522–532.
DOI: 10.1016/S1474-4422(20)30028-4

Summary

Advances in DNA sequencing technologies have resulted in a near doubling, in under 10 years, of the number of causal genes identified for inherited neuromuscular disorders. However, around half of patients, whether children or adults, do not receive a molecular diagnosis after initial diagnostic workup. Massively parallel technologies targeting RNA, proteins, and metabolites are being increasingly used to diagnose these unsolved cases. The use of these technologies to delineate pathways, biomarkers, and therapeutic targets has led to new approaches entering the drug development pipeline. However, these technologies might give rise to misleading conclusions if used in isolation, and traditional techniques including comprehensive neurological evaluation, histopathology, and biochemistry continue to have a crucial role in diagnostics. For optimal diagnosis, prognosis, and precision medicine, no single ruling technology exists. Instead, an interdisciplinary approach combining novel and traditional neurological techniques with computer-aided analysis and international data sharing is needed to advance the diagnosis and treatment of neuromuscular disorders.

diagnostic-workflow

Read next...

researcher of the year 2025

Dr. Hanns Lochmüller Awarded “Clinical Researcher of the Year” by University of Ottawa Faculty of Medicine

We are thrilled to announce that Dr. Hanns Lochmüller has been awarded the Clinical Researcher of the Year Award by the University of Ottawa Faculty...
Holland study

New Publication: Galactose treatment rescues neuromuscular junction transmission in glutamine-fructose-6-phosphate transaminase 1 (Gfpt1) deficient mice

Congenital Myasthenic Syndromes (CMS) are a group of rare inherited neuromuscular disorders caused by genetic defects at the neuromuscular junction (NMJ). Patients with CMS experience...
award winners

Celebrating Lab Members’ Recent Research Awards

We are thrilled to celebrate Kelly Ho for receiving first place for her poster presentation at this year’s American Society for Pharmacology and Experimental Therapeutics...
New publication - RTD (2)

Meet The Lochmüller Lab’s Newest Members!

Our research team is growing! We are excited to introduce three new members who have recently joined the Lochmüller lab and several students who will...
McMillan smart study (1)

New Clinical Study Examines Safety and Efficacy of IV Onasemnogene Abeparvovec in Broad SMA Cohort

Pediatric neurologist Dr Hugh McMillan publishes clinical study examining the safety and efficacy of IV onasemnogene abeparvovec in the broadest cohort of SMA patients to...
Text reading: Solve-RD publication: Solve-RD flagship publication: Genomic reanalysis of a pan-European rare-disease resource yields new diagnoses. Photos of Dr Kiran Polavarapu, Dr Rachel Thompson, Dr Hanns Lochmüller.

Solve-RD flagship publication in Nature Medicine: Genomic reanalysis of a pan-European rare-disease resource yields new diagnoses

Patients and families with rare disorders often remain without a genetic diagnosis despite modern advances in diagnostic testing. Due to the rarity and global distribution...